Mynd_Logo_2.png
MENU
mynd-menu.png
MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat Alzheimer&
Mynd Life Sciences
  • Oct 27, 2021

MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat Alzheimer&

Acquisition will strengthen MYND’s psilocybin-assisted medicinal and diagnostics capabilities, adding novel psychedelics for the...
MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Mil
Mynd Life Sciences
  • Oct 13, 2021

MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Mil

Evaluating the efficacy of psilocybin-assisted psychotherapy in treatment resistant depression VANCOUVER, BC, Oct. 13, 2021 /CNW/ – MYND...
MYND Life Sciences Inc. to Present at Psychedelics Virtual Investor Conference on October 13
Mynd Life Sciences
  • Oct 12, 2021

MYND Life Sciences Inc. to Present at Psychedelics Virtual Investor Conference on October 13

VANCOUVER, BC, Oct. 11, 2021 /PRNewswire/ — MYND Life Sciences Inc. (CSE:MYND)(OTC:MYNDF), based in Vancouver BC, focused on novel...
23
4
56
6243633205_d7126ef00c_o_edited.jpg
MYND-FUTURE.png
DIAGNOSTICS
INVESTING
SCIENCE
 
CONTACT
NEWS
  • Twitter
  • Instagram
  • LinkedIn
  • Facebook

© Copyright Mynd Life Sciences 2022

Privacy